跳至主要内容
临床试验/NCT02218645
NCT02218645已完成1 期

The Bioequivalence Between WE 941 OD Tablets (0.25mg as the Basis) and Brotizolam Conventional Tablets (Lendormin® Tablets, 0.25 mg as the Basis), Both Taken With Water, as a Single Administration in Healthy Adult Male Subjects (Open-labelled, 2-way Cross-over Study)

Boehringer Ingelheim0 个研究点目标入组 30 人开始时间: 2000年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
30
主要终点
Cmax (maximum plasma concentration)

研究概览

简要总结

The bioequivalence of WE 941 OD tablets prepared in oral disintegrating tablet form and brotizolam conventional tablets (Lendormin® tablets), both taken with water, was evaluated in healthy adult male subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Age between 20 and 35 years
  • Weight between 50 and 80 kg
  • Obesity level within the range of +/- 20% of the standard weight according to the Body Mass Index (BMI) method
  • Judged as eligible as a study object following the screening test by the investigator
  • Volunteers to participate in the study, who are capable of giving written informed consent

排除标准

  • Known hypersensitivity to drugs
  • History of drug or alcohol abuse
  • Received other investigational drug within 4 months of the trial drug administration
  • Had > 400 mL of whole blood drawn within 3 months of the trial drug administration
  • Had > 400 mL of blood components drawn within 1 month of the trial drug administration
  • Used any drug within 10 days of the trial drug administration
  • Engaged in strenuous exercise within 5 days of the trial drug administration
  • Consumed alcohol within 3 days of the trial drug administration
  • Judged as ineligible for the study participation by the investigator for a reason other than above

研究组 & 干预措施

WE 941 OD

Experimental

干预措施: WE 941 OD tablets (Drug)

Brotizolam

Active Comparator

干预措施: Brotizolam (Drug)

结局指标

主要结局

Cmax (maximum plasma concentration)

时间窗: up to 24 hours after drug administration

AUC0-24h (Area under the plasma concentration-time from 0 to 24 hours)

时间窗: up to 24 hours after drug administration

次要结局

  • tmax (time to maximum plasma concentration)(up to 24 hours after drug administration)
  • MRT (Mean residence time)(up to 24 hours after drug administration)
  • Number of patients with adverse events(up to 30 days)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验